Literature DB >> 1464422

Antibody conjugates for the treatment of cancer.

G A Pietersz1, I F McKenzie.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1992        PMID： 1464422     DOI： 10.1111/j.1600-065x.1992.tb01419.x

Source DB:  PubMed          Journal:  Immunol Rev        ISSN： 0105-2896            Impact factor:   12.988


× No keyword cloud information.
  12 in total

Review 1.  Monoclonal antibodies in cancer therapy.

Authors:  R Gruber; E Holz; G Riethmüller
Journal:  Springer Semin Immunopathol       Date:  1996

2.  Complement-independent binding of microorganisms to primate erythrocytes in vitro by cross-linked monoclonal antibodies via complement receptor 1.

Authors:  J H Powers; B L Buster; C J Reist; E Martin; M Bridges; W M Sutherland; R P Taylor; W M Scheld
Journal:  Infect Immun       Date:  1995-04       Impact factor: 3.441

3.  Diffusion of an anti-transferrin receptor antibody in cultured murine melanoma cell layers.

Authors:  V Vijaykumar; E M Topp
Journal:  Pharm Res       Date:  1995-12       Impact factor: 4.200

4.  Rice cell culture as an alternative production system for functional diagnostic and therapeutic antibodies.

Authors:  E Torres; C Vaquero; L Nicholson; M Sack; E Stöger; J Drossard; P Christou; R Fischer; Y Perrin
Journal:  Transgenic Res       Date:  1999       Impact factor: 2.788

5.  Preclinical investigation of the antitumour effects of anti-CD19-idarubicin immunoconjugates.

Authors:  A J Rowland; G A Pietersz; I F McKenzie
Journal:  Cancer Immunol Immunother       Date:  1993-08       Impact factor: 6.968

6.  Reduction in the toxicity of aminopterin--monoclonal-antibody conjugates by leucovorin.

Authors:  A J Rowland; G A Pietersz
Journal:  Cancer Immunol Immunother       Date:  1994-08       Impact factor: 6.968

7.  Preclinical studies of monoclonal antibodies for intravesical radioimmunotherapy of human bladder cancer.

Authors:  P J Russell; K Davis; E Kingsley; J Humphreys; J Hanley; H O'Grady; N Pearce
Journal:  Cell Biophys       Date:  1994

8.  Long-circulating poly(ethylene glycol)-modified gelatin nanoparticles for intracellular delivery.

Authors:  Goldie Kaul; Mansoor Amiji
Journal:  Pharm Res       Date:  2002-07       Impact factor: 4.200

Review 9.  Enzymatic Transition States and Drug Design.

Authors:  Vern L Schramm
Journal:  Chem Rev       Date:  2018-10-18       Impact factor: 60.622

10.  Targeted radioimmunotherapy with the iodine-131-labeled caerin 1.1 peptide for human anaplastic thyroid cancer in nude mice.

Authors:  Ruoting Lin; Bowei Ma; Na Liu; Lu Zhang; Tiantian He; Xiongying Liu; Tongsheng Chen; Wenjuan Liu; Yongnan Liang; Tianfang Wang; Guoying Ni; Xiaosong Liu; Ning Yang; Jinhe Zhang; Jianwei Yuan
Journal:  Ann Nucl Med       Date:  2021-05-04       Impact factor: 2.668
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.